Preclinical studies have also demonstrated that PARP2 plays a protective role against replicative stress in hematopoietic stem/progenitor cells, and depletion of PARP2 leads to anemia.24,25 PARP inhibitors are known to cause hematologic toxicities in patients with different tumor types.26 The phase III EMBRACA and phase II ABRAZO trials established the safety profile of talazoparib in female and male patients with advanced breast cancer.27-30 The most common hematologic toxicities were anemia, neutropenia, and thrombocytopenia.28-31. This evidence concerns the gene PARP2 and neoplasm.